ESC Premium Access

Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation: Prospective KYU-RABLE study

Congress Session

About the speaker

Professor Naohiko Takahashi

Oita University Faculty of Medicine, Oita (Japan)
0 follower

7 more presentations in this session

Use of Non-vitamin K antagonist Oral Anticoagulants in a real-world setting: a community pharmacy-based study.

Speaker: Mr A. Capiau (Ghent, BE)

Thumbnail

Potential real-world benefits of low-dose rivaroxaban in Chinese stable cardiovascular patients

Speaker: Associate Professor B. Yan (Hong Kong, HK)

Thumbnail

Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study.

Speaker: Doctor M. Vedovati (Perugia, IT)

Thumbnail

Risk of arterial calcification by conventional vitamin K antagonist treatment

Speaker: Doctor S. Hasific (Odense, DK)

Thumbnail

Real world persistence with direct oral anticoagulants in anticoagulation naive patients with atrial fibrillation

Speaker: Doctor G. Denas (Padua, IT)

Thumbnail

Access the full session

Perspectives on anticoagulation across cardiovascular disease

Speakers: Professor N. Takahashi, Mr A. Capiau, Associate Professor B. Yan, Doctor M. Vedovati, Doctor S. Hasific...
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

Related content

Open Access

Welcome and introduction.

21 May 2022

EHRA Premium Access

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

4 April 2022

ESC Premium Access

Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

28 August 2021

This platform is supported by

logo Novo Nordisk